Viking Therapeutics Inc buy stratec
Summary
This prediction ended on 05.11.21 with a price of €5.81. The BUY prediction by stratec for Viking Therapeutics Inc performed very badly with a performance of -66.75%. stratec has 50% into this predictionPerformance without dividends (%)
| Name | 1w | 1m | 1y | 3y |
|---|---|---|---|---|
| Viking Therapeutics Inc | 29.814% | 29.814% | 372.134% | 1172.308% |
| iShares Core DAX® | 1.280% | 1.320% | 13.605% | 15.782% |
| iShares Nasdaq 100 | -2.457% | -5.192% | 25.941% | 38.434% |
| iShares Nikkei 225® | -2.006% | -1.389% | 8.973% | 6.570% |
| iShares S&P 500 | -0.662% | -1.884% | 23.684% | 39.611% |
Comments by stratec for this prediction
In the thread Viking Therapeutics Inc diskutieren
Viking Therapeutics is still undervalued
Viking Therapeutics recently released positive data from an NAFLD clinical trial.
The NAFLD market is a massive one with serious unmet medical need.
After digging into the company's most recent financial report, I was pleasantly surprised.
I believe that Viking Therapeutics has incredible upside potential.
At the end of November the company announced positive results from a 12-week mid-stage study evaluating VK5211 in patients who recently suffered a hip fracture. The drug candidate is an orally
available, non-steroidal selective androgen receptor modulator (SARM) which was created to stimulate bone and muscle formation with a reduction of activity in peripheral tissues.
Jay Magaziner, PhD, MSHyg, Professor and Chair, Department of Epidemiology and Public Health at the University of Maryland School of Medicine, had the following commentary:
The degree of improvement in lean body mass in this group of older persons who are prone to losing muscle is impressive. Having a drug like this available that can be taken easily and safely soon after hip fracture would provide a valuable adjunct to other therapeutic strategies such as physical therapy and a protein-rich diet to boost patients' chances for resuming usual activities.
In the future one can expect further updates on endpoints including exploratory measures of functional performance. Considering that the drug candidate could have blockbuster potential and even if peak sales were $500 million to be ultra conservative, based on this one candidate alone it would seem the company is undervalued. According to the company there are around 300,000 patients per year in the United States for the target indication.
08.10.2018
The results demonstrated that treatment with VK2809 led to anoverall improvement in liver health highlighted by restoration of autophagy, reduction in steatosis, and improvements in inflammation and
liver size. The study investigators concluded that these histological improvements are potentially relevant to non-alcoholic fatty liver disease, including non-alcoholic steatohepatitis, due to certain similarities between those conditions and GSD Ia.
Importantly, this study also demonstrated indications of reduced inflammatory signalling following treatment with VK2809.
In the thread Trading Viking Therapeutics Inc
Stopped prediction by stratec for Viking Therapeutics Inc
Viking Therapeutics Inc
22.12.17
18.09.18
18.09.18
